Quarterly Result23 Oct 2025, 03:29 pm
Laurus Labs Announces H1 FY26 Results: Revenues at INR 3,223 Cr, EBITDA at INR 818 Cr, 25.4% Margins
AI Summary
Laurus Labs, a leading research and development driven pharmaceutical and biotech company in India, has announced its Q2 & H1 FY26 results. The company reported revenues of INR 1,653 Cr for Q2 FY26 and INR 3,223 Cr for H1 FY26, representing a 35% and 33% year-over-year growth respectively. The EBITDA stood at INR 429 Cr for Q2 FY26 and INR 818 Cr for H1 FY26, reflecting a 136% and 132% year-over-year growth respectively. The EBITDA margins were reported at 26.0% for Q2 FY26 and 25.4% for H1 FY26.
Key Highlights
- Revenues of INR 1,653 Cr for Q2 FY26, representing a 35% year-over-year growth
- EBITDA of INR 429 Cr for Q2 FY26, representing a 136% year-over-year growth
- EBITDA margins at 26.0% for Q2 FY26
- Revenues of INR 3,223 Cr for H1 FY26, representing a 33% year-over-year growth
- EBITDA of INR 818 Cr for H1 FY26, representing a 132% year-over-year growth
- EBITDA margins at 25.4% for H1 FY26